Micvotabart pelidotin, an experimental antibody-drug conjugate, posted a 39% confirmed response rate in an early Phase 1 study in recurrent or metastatic head and neck cancer. The results were reported from an initial cohort treated with the AUC-based candidate, positioning the drug as a lead ADC signal in a difficult-to-treat setting. The study adds to a growing ADC readout pipeline in head and neck oncology, where response rates can vary widely across mechanisms and dosing schedules. The reported confirmed-response figure suggests meaningful activity beyond historical single-agent expectations, though the data remain preliminary given the early-phase design. Clinicians will look for durability, biomarker signals, and a safety profile that supports continued dose optimization and cohort expansion in future study phases.